This new drug has a bright future ahead
“We are very pleased that the FDA has granted QIDP designation to BIOC51,” Anne Whitaker, chief executive officer of Novoclem Therapeutics, said in the release. “Chronic, persistent lung infections with Pseudomonas aeruginosa are a major factor impacting the poor quality of life and untimely death in cystic fibrosis patients. The QIDP designation will accelerate the advancement of BIOC51 development as a potential treatment for these patients.”
Novoclem is planning to submit an Investigational New Drug application for BIOC51 as a first step to beginning clinical trials in cystic fibrosis patients in 2018.